Distribution Modernization

Canadian Blood Services is responsible for securing and providing plasma protein and related products (PPRP) to hospitals across Canada for use by clinicians and their patients in all provinces and territories (except Quebec). Currently, patients using products at home generally pick up their supply from the hospital and then administer the treatment at home.

Canadian Blood Services is piloting a program for home delivery to eligible patients in Alberta using Bayshore Pharmacy, a specialty pharmacy. The purpose of this pilot is to demonstrate that this is a feasible option for providing home care PPRP to patients, while increasing Canadian Blood Services’ access to product use data. Getting data from Bayshore Pharmacy on the use of PPRP will allow Canadian Blood Services to better manage PPRP access, demand planning, and inventory management.

Canadian Blood Services is responsible for securing and providing plasma protein and related products (PPRP) to hospitals across Canada for use by clinicians and their patients in all provinces and territories (except Quebec). Currently, patients using products at home generally pick up their supply from the hospital and then administer the treatment at home.

Canadian Blood Services is piloting a program for home delivery to eligible patients in Alberta using Bayshore Pharmacy, a specialty pharmacy. The purpose of this pilot is to demonstrate that this is a feasible option for providing home care PPRP to patients, while increasing Canadian Blood Services’ access to product use data. Getting data from Bayshore Pharmacy on the use of PPRP will allow Canadian Blood Services to better manage PPRP access, demand planning, and inventory management.

  • CLOSED: This survey has concluded.

    Distribution Modernization Survey for Clinic and Hospital Customers

    You are receiving this survey because you are involved in the care of patients receiving Hemlibra (emicizumab) and/or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information about clinic and hospital customers’ experiences to further improve the project.  This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.

    The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides Canadian Blood Services with dispensing data to help us better understand how these products are being used, and ensure patients have access to the best possible care. 

    Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.

    The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us. 

  • CLOSED: This survey has concluded.

    Distribution Modernization Survey for Patients

    You are receiving this survey because you are either a patient or a caregiver of a patient receiving Hemlibra (emicizumab) or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information to further improve the project. This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.

    The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides valuable information about how these medications are being used, which helps Canadian Blood Services support patient access to the best possible care. 

    Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.

    The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us.

Page last updated: 07 Apr 2025, 08:32 AM